Patents by Inventor Nikolaos Vasilakis

Nikolaos Vasilakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230153109
    Abstract: A system for analysis and steering use of online libraries, contains program source code comprising a plurality of modules, at least one third party library, and a processor and a memory configured to store non-transitory instructions that, when executed by the processor, run a module recontextualization application. The module recontextualization application is configured to decompose a program within the third-party library at boundaries of modules of the program, apply transformations to the decomposed program to insert analysis specific code, and reassemble individual components of the decomposed program to maintain original semantics of the program, while incorporating the transformations that were applied to the decomposed program.
    Type: Application
    Filed: November 16, 2022
    Publication date: May 18, 2023
    Inventors: Martin C. Rinard, Nikolaos Vasilakis
  • Publication number: 20230142816
    Abstract: The disclosure describes an integrated fluid sample test strip comprising: an inlet for receiving solutions comprising a fluid sample and a substrate solution, the inlet comprising a retention valve for temporarily retaining each solution to thereby reduce air flow through the valve; a reaction chamber to receive the solutions via the retention valve, the chamber functionalized with bioreceptor(s); a capillary pump to receive from the reaction chamber the solution(s), the pump comprising vent hole(s); a test chamber to receive the substrate solution from the reaction chamber, the test chamber comprising test electrodes for a biosensing test of the substrate solution; a hydrophobic vent hole coupled to the test chamber to allow a flow of solution from the reaction chamber into the test chamber when the vent hole is unsealed and to allow a flow of solution from the reaction chamber to the capillary pump when the vent hole is sealed.
    Type: Application
    Filed: March 12, 2021
    Publication date: May 11, 2023
    Inventors: Nikolaos VASILAKIS, Richard WHITE, Stefano BORINI, Cedric HURTH
  • Publication number: 20230139429
    Abstract: A privilege metric application quantifies a privilege reduction for a subject software module MS. Target critical resources Mt accessible by the subject module are identified. Permissions P(MS, Mt) for the subject module to access each of the target critical resources as a result of the privilege reduction are determined. Default library permissions Pbase(MS, Mt) without the privilege reduction are determined. A metric regarding the vulnerability reduction of P(MS, Mt) with respect to Pbase(MS, Mt) is quantified.
    Type: Application
    Filed: October 31, 2022
    Publication date: May 4, 2023
    Inventor: Nikolaos Vasilakis
  • Patent number: 8993744
    Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: March 31, 2015
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Nikolaos Vasilakis
  • Publication number: 20130071419
    Abstract: Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP.
    Type: Application
    Filed: May 23, 2011
    Publication date: March 21, 2013
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Ted M. Ross, Nikolaos Vasilakis
  • Publication number: 20120294889
    Abstract: The invention provides chimeric flavivirus vectors encoding one or more structural proteins from a first flavivirus with a low level of replication in a cell, such as dengue virus and yellow fever virus, and a backbone from a second flavivirus with a high level of replication in the cell, such as the Rio Bravo virus or the Uganda S virus. The chimeric flaviviruses encoded by the chimeric flavivirus vectors of the invention can be used to vaccinate subjects to prevent infection from infectious flaviviruses, including dengue viruses and yellow fever viruses.
    Type: Application
    Filed: November 11, 2011
    Publication date: November 22, 2012
    Applicant: PAXVAX, INC.
    Inventors: Thomas P. Monath, Nikolaos Vasilakis
  • Patent number: 7541038
    Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.
    Type: Grant
    Filed: June 2, 2004
    Date of Patent: June 2, 2009
    Assignee: Wyeth Holdings Corporation
    Inventors: Gerald Raul Kovacs, Xiaoyan Mo, Nikolaos Vasilakis, Sangeeta Bhargava, Timothy Joseph Zamb, Stephen Alexander Udem
  • Publication number: 20070128222
    Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.
    Type: Application
    Filed: June 2, 2004
    Publication date: June 7, 2007
    Applicant: Wyeth Holdings Corporation
    Inventors: Gerald Kovacs, Xiaoyan Mo, Nikolaos Vasilakis, Sangeeta Bhargava, Timothy Zamb, Stephen Udem
  • Publication number: 20060141602
    Abstract: The invention generally relates to recombinant polynucleotides, positive-strand RNA virus (psRNAV) recombinant expression vectors, and packaging systems. The packaging systems are based on the expression of helper functions by coinfecting re-combinant poxvirus vectors comprising recombinant polynucleotides. Methods for obtaining psRNAV replicon particles using these packaging systems are disclosed. Immunogenic compositions and pharmaceutical formulations are provided that comprise replicon particles of the invention. Methods for generating an immune response or producing a pharmaceutical effect are also provided.
    Type: Application
    Filed: December 8, 2005
    Publication date: June 29, 2006
    Applicant: Wyeth Holdings Corporation
    Inventors: Gerald Kovacs, Nikolaos Vasilakis, Jacek Kowalski, Seema Gangolli, Timothy Zamb